COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

OCCPR Webinar: LinkedOmics

Scientists from the Clinical Proteomics Tumor Analysis Consortium (CPTAC) program developed a powerful tool to explore associations between multiple types of omics datasets.  The LinkedOmics software collects genomic, transcriptomic and proteomic datasets from


CPTAC Researchers Identify New Features of Ovarian High-Grade Serous Cancer Associated with Patient Survival Rates and Alternative Drug Therapies

In a study published on April 21, in Cell Reports Medicine, researchers with the National Cancer Institutes’ (NCI) Clinical Proteomics Tumor Analysis Consortium (CPTAC) take a comprehensive look at the root causes of ovarian high-grade serous carcinoma (HGSC).  Through integrated proteomic and genomic an


150 New Assays on the NCI Assay Portal!

One of the missions of theClinical Proteomic Tumor Analysis Consortium (CPTAC) is to provide proteomic resources to the greater scientific community.  So, we have great news to announce!  CPTAC has added 150 "fit-for-purpose," multiplexed, mass spectrometry-based proteomic targeted assays to its Assay Portal!


New Quarterly Release of CPTAC Radiology Imaging Data Available

It’s that time again!  CPTAC radiology images have been released on the TCIA CPTAC Pathology Portal!  Between conference calls and literature searches, take a look at the 38 new radiology and 8 new pathology images added to Portal – all for free!


OCCPR Webinar: Network Exploration Tool for Cancer Research

Finding novel interactions from comprehensive genomics and proteomics (mass spectrometry generated) is made significantly easier with the help of a visual, interactive guide.


The Proteomic Data Commons Is Now Live!

NCI announces the launch of the NCI Proteomic Data Commons (PDC)!


New CPTAC Imaging Data Available

New histopathology slides available from CPTAC lung squamous cell carcinoma, lung adenocarcinoma and glioblastoma multiforme studies. 149 images from 28 new cases added in the month of February 2020 are publicly available on the TCIA CPTAC Pathology Portal!


Making Space for Ubiquitin Proteomics

Protein ubiquitylation is best known for its role in degradation, leading molecules to the cell’s recycle bin, but it also has roles in cellular processing and protein interactions.  Unfortunately, research using proteomic techniques have been limited due to experimental and technical complications.    


OCCPR Webinar: The Cancer Imaging Archive

The Cancer Imaging Archive (TCIA) houses radiology and histopathology data for the CPTAC Program.  There are over 1500 cases and with more than 6000 images…and counting…of 10 cancer types freely available for the public to view.  Each case has complementary proteomic data through the Proteomic Data Commons and genomic data through the


New, Detailed Molecular Roadmap Boosts Fight Against Endometrial Cancer

After 12 million measurements, new drug targets emerge


Pages